The Government has announced a package of steps intended to strengthen brain-cancer research and move promising discoveries towards clinical use. It includes an expert review due within three months, a national action plan to follow, a new clinical lead and an accelerated review of rules for medicines developed for rare conditions.
The announcement follows a meeting between Prime Minister Andy Burnham, Health and Social Care Secretary Yvette Cooper and brain-cancer campaigner Archie Goodburn. The immediate review will be led by Professor Anthony Chalmers, who chairs the Brain Tumour Group within the UK Collaborative for Cancer Clinical Research. Experts will examine what has changed for patients since a government review in 2018 and identify obstacles that continue to hinder progress.
A review before an action plan
The review is expected to report within three months. Its findings are intended to shape a national action plan focused on getting treatments from laboratory research to patients more quickly. That sequence matters: the plan is a future commitment, and its content will depend on the review. The announcement does not set out specific treatments, clinical outcomes or a delivery timetable for the action plan.
The Department of Health and Social Care also intends to appoint a national brain-cancer clinical lead to drive the work forward. The appointment has not yet been made; the department says it will announce the lead in due course. The role is part of the proposed national coordination, rather than a new clinical service or a change to individual care.
A separate regulatory commitment concerns the review of rules for medicines intended for rare conditions, known as orphan drugs. The Prime Minister has asked the Medicines and Healthcare products Regulatory Agency to complete that review in two years rather than three. The review is required by the Rare Cancers Act 2026. The Government says possible changes could help promising treatments reach patients sooner, but the review itself does not approve any medicine or guarantee access to a treatment. No specific rule changes have been announced.
More attention to clinical-trial participation
Patients, families and charities are also expected to help design work to encourage more people to join clinical trials. The Health and Social Care Secretary is to host a roundtable with researchers, clinicians and charities to explore ways to increase participation. Ministers say they will work with researchers and industry to make the UK a better place to run trials, with the aim of widening opportunities to access promising treatments.
The National Institute for Health and Care Research is supporting 59 brain-tumour studies across the country, including 35 clinical trials testing new treatments, according to the announcement. Those figures describe studies and trials receiving support; they do not indicate how many people have enrolled, whether a particular patient is eligible, or whether a treatment has been shown to work. The Government says the studies need participants with different types of brain tumours and could contribute to improving therapies now and in future.
The department also plans to work with Cancer Research UK next year to bring global experts together and promote British brain-cancer research. The partner organisation has welcomed the wider commitments, including work on trial access and a planned 2027 brain-tumour conference. These are intended activities, not completed outcomes.
What remains to be delivered
The package sets out a process and several intended responsibilities rather than announcing a new treatment. Its immediate test will be whether the expert review arrives on schedule and produces findings that can guide a practical action plan. The clinical lead still needs to be appointed, and the medicines-rules review is expected to take two years.
For patients and families, the announcement signals renewed attention to research barriers and trial participation, while leaving important questions open. It does not identify which barriers will be prioritised, specify future rule changes, or promise that research will produce an effective treatment. The stated aim is to improve the path from research to care; whether these commitments lead to faster development or wider access will depend on the work that follows.
